Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 10/21 10:00:15 pm
61.2 USD   -1.16%
03:58a MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in A..
10/20MERCK & CO., IN : quaterly earnings release
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
03:58a MERCK : FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recu..
10/21 MERCK : ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Blad..
10/20 MERCK : New Findings from Merck & Company Describe Advances in Clinical Trials a..
10/20 MERCK : Findings on Pneumonia Reported by Researchers at Merck & Company (Ceftol..
10/20 NEW PEPTIDE HYDROLASES STUDY RESULTS : Improving Aqueous Solubility...
10/20 MERCK : Studies from Merck Research Labs in the Area of Thrombosis Reported (Dif..
10/20MERCK & CO., INC. : quaterly earnings release
10/19 MERCK : Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antivi..
10/18 MERCK : Country Club Trust Company N.a. Lowers stake in Merck & Co.
10/17 MERCK : Research Laboratories Facilities Designated as “Milestones in Micr..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/21 HERE'S HOW LILLY AND MERCK ARE FARIN : Earnings Out Next Week
10/21 Why You (And Another Company) Should Buy Gilead - Dividend Sensei
10/21 Merck's Keytruda successful in late-stage bladder cancer study
10/20 The Drug Battle Coming To A Neighborhood Near You
10/19 How Do Recent Developments In The Approval Process For Heplisav-B By Dynavax ..
Financials ($)
Sales 2016 39 696 M
EBIT 2016 13 597 M
Net income 2016 5 663 M
Debt 2016 5 348 M
Yield 2016 2,97%
P/E ratio 2016 30,00
P/E ratio 2017 19,78
EV / Sales 2016 4,40x
EV / Sales 2017 4,30x
Capitalization 169 231 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.87%169 231
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.36%198 298
PFIZER INC.-0.31%195 193
More Results